C3-halogenation of cytisine generates potent and efficacious nicotinic receptor agonists

被引:29
作者
Abin-Carriquiry, JA
Voutilainen, MH
Barik, J
Cassels, BK
Iturriaga-Vásquez, P
Bermudez, I
Durand, C
Dajas, F
Wonnacott, S [1 ]
机构
[1] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England
[2] IIBCE, Montevideo, Uruguay
[3] Univ Chile, Fac Sci, Dept Chem, Santiago, Chile
[4] Oxford Brookes Univ, Sch Biol & Mol Sci, Oxford OX3 0BP, England
基金
英国惠康基金;
关键词
nicotinic acetylcholine receptor; dopamine release; noradrenaline release; H-3]epibatidine binding; H-3]methyllycaconitine binding; Xenopus oocyte;
D O I
10.1016/j.ejphar.2006.02.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Neuronal nicotinic acetylcholine receptors subserve predominantly modulatory roles in the brain, making them attractive therapeutic targets. Natural products provide key leads in the quest for nicotinic receptor subtype-selective compounds. Cytisine, found in Leguminosae spp., binds with high affinity to alpha 4 beta 2* nicotinic receptors. We have compared the effect of C3 and C5 halogenation of cytisine and methylcytisine (MCy) on their interaction with native rat nicotinic receptors. 3-Bromocytisine (3-BrCy) and 3-iodocytisine (3-ICy) exhibited increased binding affinity (especially at alpha 7 nicotinic receptors; K-1 similar to 0.1 mu M) and functional potency, whereas C5-halogenation was detrimental. 3-BrCy and 3-ICy were more potent than cytisine at evoking [H-3]dopamine release from striatal slices (EC50 similar to 11 nM), [H-3]noradrenaline release from hippocampal slices (EC50 similar to 250 nM), increases in intracellular Ca2+ in PC12 cells and inward currents in Xenopus oocytes expressing human alpha 3 beta 4 4 nicotinic receptor (EC50 similar to 2 mu M). These compounds were also more efficacious than cytisine. C3-halogenation of cytisine is proposed to stabilize the open conformation of the nicotinic receptor but does not enhance subtype selectivity. (c) 2006 Elsevier B.V All rights reserved.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 39 条
  • [31] Characterization of nicotinic acetylcholine receptor-mediated [3H]-dopamine release from rat cortex and striatum
    Puttfarcken, PS
    Jacobs, I
    Faltynek, CR
    [J]. NEUROPHARMACOLOGY, 2000, 39 (13) : 2673 - 2680
  • [32] ROGERS SW, 1992, J NEUROSCI, V12, P4611
  • [33] Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice
    Salminen, O
    Murphy, KL
    McIntosh, JM
    Drago, J
    Marks, MJ
    Collins, AC
    Grady, SR
    [J]. MOLECULAR PHARMACOLOGY, 2004, 65 (06) : 1526 - 1535
  • [34] SEGUELA P, 1993, J NEUROSCI, V13, P596
  • [35] Sharples CGV, 2000, J NEUROSCI, V20, P2783
  • [36] Synthesis and pharmacological characterization of novel analogues of the nicotinic acetylcholine receptor agonist (±)-UB-165
    Sharples, CGV
    Karig, G
    Simpson, GL
    Spencer, JA
    Wright, E
    Millar, NS
    Wonnacott, S
    Gallagher, T
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (15) : 3235 - 3245
  • [37] Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes
    Slater, YE
    Houlihan, LM
    Maskell, PD
    Exley, R
    Bermúdez, I
    Lukas, RJ
    Valdivia, AC
    Cassels, BK
    [J]. NEUROPHARMACOLOGY, 2003, 44 (04) : 503 - 515
  • [38] Chemical modification of epibatidine causes a switch from agonist to antagonist and modifies its selectivity for neuronal nicotinic acetylcholine receptors
    Spang, JE
    Bertrand, S
    Westera, G
    Patt, JT
    Schubiger, PA
    Bertrand, D
    [J]. CHEMISTRY & BIOLOGY, 2000, 7 (07): : 545 - 555
  • [39] Whiteaker P, 2000, MOL PHARMACOL, V57, P913